Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)
✉ Email this page to a colleague
Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)
| Docket | ⤷ Sign Up | Date Filed | 2023-06-23 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | Defendant | Referred To | |
| Patents | 10,034,877; 9,486,526 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-12-20 | 31 | Redacted Document | U.S. Patent Nos. 9,486,526 (“the 526 patent”) and 10,034,877 (“the 877 patent”) (“the patents-in-suit… that the claims of the 526 patent are infringed. All of the 526 patent’s claims recite a method for …CONFIDENTIAL—FILED UNDER SEAL 877 patent are infringed. All of the 877 patent’s claims require treating a patient…claimed uses of the patents-in-suit. “To prevail on a theory of induced patent infringement, a plaintiff… or patients, to infringe the patent by using the drug for the patented use. Warner-Lambert, 316 F.3d | External link to document |
| 2024-01-31 | 43 | Redacted Document | The patents asserted in this action are: U.S. Patent Nos. 9,486,526 (“the ’526 Patent”) and 10,034,877…adjustment. See D.I. 2, Ex. 1 (’526 Patent), Ex. 2 (’877 Patent). …manner that infringes the Asserted Patents. In the context of patents for methods of treatment involving…many other claims of the Asserted Patents, claim 13 of the ’877 patent recites a method for treating T2DM….5 C. Tradjenta® and the Asserted Patents ............................................... | External link to document |
| 2024-04-02 | 55 | Notice of Service | Noninfringement Contentions Regarding U.S. Patent Nos. 9,486,526 and 10,034,877 and Apotex Inc. and Apotex Corp.…Invalidity Contentions Regarding U.S. Patent Nos. 9,486,526 and 10,034,877 filed by Apotex Corp., Apotex Inc… 23 June 2023 1:23-cv-00685 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2024-06-07 | 59 | Notice of Service | Associate with ANDA No. 218552 for U.S. Patent Nos. 9,486,526 and 10,034,877; and (2) Plaintiffs' Response to… 23 June 2023 1:23-cv-00685 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
